Welcome to LookChem.com Sign In|Join Free

CAS

  • or

57133-29-6

Post Buying Request

57133-29-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

57133-29-6 Usage

Description

BOC-ORN(BOC)-OH, also known as Nα-BOC-L-Ornithine, is a protected amino acid derivative that serves as a crucial building block in the synthesis of peptides. It is characterized by the presence of a tert-butyloxycarbonyl (BOC) group, which provides protection to the amino group during peptide synthesis, preventing unwanted side reactions. BOC-ORN(BOC)-OH is essential in the pharmaceutical and biotechnology industries due to its role in creating various peptide-based drugs and therapeutics.

Uses

BOC-ORN(BOC)-OH is used as an amino acid building block for peptide synthesis, which is of great importance in the growing peptide drug market. The fast and reliable synthesis of peptides is crucial for the development of new drugs and therapies.
Used in Pharmaceutical Industry:
BOC-ORN(BOC)-OH is used as a key component in the synthesis of various peptide-based drugs. Its role in peptide synthesis allows for the creation of a wide range of therapeutic peptides with potential applications in treating various diseases and conditions.
Used in Biotechnology Industry:
In the biotechnology sector, BOC-ORN(BOC)-OH is utilized for the development of novel bioactive peptides with specific functions. These peptides can be employed in research, diagnostics, and therapeutic applications, contributing to the advancement of biotechnological solutions for various industries.
Overall, BOC-ORN(BOC)-OH plays a significant role in the synthesis of peptides, which has a wide range of applications in the pharmaceutical and biotechnology industries. Its use in creating peptide-based drugs and therapeutics is essential for the development of new treatments and therapies for various diseases and conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 57133-29-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,1,3 and 3 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 57133-29:
(7*5)+(6*7)+(5*1)+(4*3)+(3*3)+(2*2)+(1*9)=116
116 % 10 = 6
So 57133-29-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H28N2O6/c1-14(2,3)22-12(20)16-9-7-8-10(11(18)19)17-13(21)23-15(4,5)6/h10H,7-9H2,1-6H3,(H,16,20)(H,17,21)(H,18,19)/p-1/t10-/m0/s1

57133-29-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-2,5-bis[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid

1.2 Other means of identification

Product number -
Other names N,N'-Bis-Boc-L-ornithine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:57133-29-6 SDS

57133-29-6Relevant articles and documents

Ornithine-derived oligomers and dendrimers forin vitrodelivery of DNA andex vivotransfection of skin cellsviasaRNA

Alexander, Cameron,Blakney, Anna K.,Bouton, Clément R.,Conte, Claudia,Gurnani, Pratik,Lovato, Tatiana,Quaglia, Fabiana,Russo, Annapina,Russo, Giulia,Saviano, Francesca,Shattock, Robin J

, p. 4940 - 4949 (2020)

Gene therapies are undergoing a renaissance, primarily due to their potential for applications in vaccination for infectious diseases and cancers. Although the biology of these technologies is rapidly evolving, delivery strategies need to be improved to overcome the poor pharmacokinetics and cellular transport of nucleic acids whilst maintaining patient safety. In this work, we describe the divergent synthesis of biodegradable cationic dendrimers based on the amino acid ornithine as non-viral gene delivery vectors and evaluate their potential as delivery vectors for DNA and RNA. The dendrimers effectively complexed model nucleic acids at lower N/P ratios than polyethyleneimine and outperformed it in DNA transfection experiments with ratios above 5. Remarkably, all dendrimer polyplexes at N/P = 2 achieved up to 7-fold higher protein content over an optimized PEI formulation when used for transfections with self-amplifying RNA (saRNA). Finally, transfection studies utilizing human skin explants revealed an increase of cells producing protein from 2% with RNA alone to 12% with dendrimer polyplexes, attributed to expression enrichment predominantly in epithelial cells, fibroblasts and leukocytes, with minor enrichment in NK cells, T cells, monocytes, and B cells. Overall, this study indicates the clear potential of ornithine dendrimers as safe and effective delivery vectors for both DNA and RNA therapeutics.

Quinone-amino acid conjugates targeting leishmania amino acid transporters

Prati, Federica,Goldman-Pinkovich, Adele,Lizzi, Federica,Belluti, Federica,Koren, Roni,Zilberstein, Dan,Bolognesi, Maria Laura

, (2015/01/08)

The aim of the present study was to investigate the feasibility of targeting Leishmania transporters via appropriately designed chemical probes. Leishmania donovani, the parasite that causes visceral leishmaniasis, is auxotrophic for arginine and lysine and has specific transporters (LdAAP3 and LdAAP7) to import these nutrients. Probes 1-15 were originated by conjugating cytotoxic quinone fragments (II and III) with amino acids (i.e. arginine and lysine) by means of an amide linkage. The toxicity of the synthesized conjugates against Leishmania extracellular (promastigotes) and intracellular (amastigotes) forms was investigated, as well their inhibition of the relevant amino acid transporters. We observed that some conjugates indeed displayed toxicity against the parasites; in particular, 7 was identified as the most potent derivative (at concentrations of 1 μg/mL and 2.5 μg/mL residual cell viability was reduced to 15% and 48% in promastigotes and amastigotes, respectively). Notably, 6, while retaining the cytotoxic activity of quinone II, displayed no toxicity against mammalian THP1 cells. Transport assays indicated that the novel conjugates inhibited transport activity of lysine, arginine and proline transporters. Furthermore, our analyses suggested that the toxic conjugates might be translocated by the transporters into the cells. The non-toxic probes that inhibited transport competed with the natural substrates for binding to the transporters without being translocated. Thus, it is likely that 6, by exploiting amino acid transporters, can selectively deliver its toxic effects to Leishmania cells. This work provides the first evidence that amino acid transporters of the human pathogen Leishmania might be modulated by small molecules, and warrants their further investigation from drug discovery and chemical biology perspectives.

Staphyloferrin A as siderophore-component in fluoroquinolone-based Trojan horse antibiotics

Milner, Stephen J.,Seve, Alexandra,Snelling, Anna M.,Thomas, Gavin H.,Kerr, Kevin G.,Routledge, Anne,Duhme-Klair, Anne-Kathrin

, p. 3461 - 3468 (2013/06/26)

A series of fluoroquinolone conjugates was synthesised by linking the carboxylic acid functionality of the carboxylate-type siderophore staphyloferrin A and its derivatives to the piperazinyl nitrogen of ciprofloxacin and norfloxacin via amide bond formation. Four siderophore-drug conjugates were screened against a panel of bacteria associated with infection in humans. Whilst no activity was found against ciprofloxacin- or norfloxacin-resistant bacteria, one of the conjugates retained antibacterial activity against fluoroquinolone-susceptible strains although the structure of its lysine-based siderophore component differs from that of the natural siderophore staphyloferrin A. In contrast, three ornithine-based siderophore conjugates showed significantly reduced activity against strains that are susceptible to their respective parent fluoroquinolones, regardless of the type of fluoroquinolone attached or chirality at the ornithine Cα-atom. The loss of potency observed for the (R)- and (S)-ornithine-based ciprofloxacin conjugates correlates with their reduced inhibitory activity against the target enzyme DNA gyrase. The Royal Society of Chemistry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 57133-29-6